DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Loop diuretics, 682–686, 683t
absorption and elimination of, 685
adverse effects and contraindications
to, 685–686
as antihypertensive agents, 774t, 777
chemistry of, 682, 683t
drug interactions with, 685–686
excretory and renal hemodynamic
effects of, 678t, 684–685
mechanism of action of, 682–684
pharmacology of, 683t, 684–685
and renal hemodynamics, 685
site of action of, 682–684
structure of, 683t
therapeutic uses of, 686
for heart failure, 790–791
toxicity of, 685–686
and urinary excretion, 684–685
Loop of Henle, 673
LO/OVRAL (ethinyl estradiol/norgestrel),
1835t
Loperamide, 507–508
for diarrhea, 1337–1338
quinidine and, 91
structure of, 504f
Loperamide, ABC transporters and,
105t
LOPID (gemfibrozil), 903
Lopinavir, 1626t, 1651–1652
pharmacokinetics of, 1651, 1858t
structure of, 1648f
LORABID (loracarbef f), 1494t
Loracarbef
chemistry of, 1494t
dosage and dosage forms of, 1494t
Loratadine, 922t, 924, 1816
pharmacokinetics of, 920, 1802,
1816t, 1858t
structure of, 919f
Lorazepam
administration of, 466t
pharmacokinetics of, 128t, 1859t
structure of, 459t
therapeutic uses of, 466t
as antinausea agent, in cancer
chemotherapy, 1344t
Lornoxicam, 990
Losartan, 736
as antihypertensive agent, 774t,
785–786
clinical pharmacology of, 738
pharmacokinetics of, 1859t
structure of, 737f
therapeutic uses of, 738–745
LOTENSIN (benazepril), 733
Lotion(s), 1807t
Lou Gehrig’s disease. See
Amyotrophic lateral sclerosis
(ALS)
Lovastatin, 893
chemistry of, 894
dosage of, required to achieve
reduction in LDL-C, 895t
history of, 893
pharmacokinetics of, 895–896,
1859t
polymorphisms and response to,
159t
structure of, 893f
therapeutic uses of, 897
in children, 898
Low-density lipoprotein (LDL)
plasma levels
bile acid sequestrants and, 899
classification of, 887t
receptor, 883
Low-density lipoprotein–receptorrelated
protein (LRP), 881
Low-density lipoproteins (LDL), 877,
878, 882–883
characteristics of, 879t
gemfibrozil and, 902
lipid-depleted, 877–878
nicotinic acid and, 900
plasma
bile acid sequestrants and, 899
goals, 886t
levels, treatment based on, 886t
reduction of, statin doses required
for, 895t
statins and, 894
Low-flow oxygen administration, 559
Low molecular weight heparin
(LMWH)
absorption, 857
administration and monitoring of,
858
clinical use and monitoring of, 865
features of, 854t
mechanism of action of, 854–855,
856f
pharmacokinetics of, 857
therapeutic uses of, 855–857
thrombocytopenia caused by, 859
Loxapine
dosage of, 424t
potencies at neurotransmitter
receptors, 427t
side effects of, 424t
LOZOL (indapamide), 688t
LPL. See Lipoprotein lipase (LPL)
LRP. See Low-density lipoprotein
receptor-related protein
LSD. See Lysergic acid diethylamide
(LSD)
L-selectin, in inflammation, 960
LUCENTIS (ranibizumab),
1739, 1794
Lugol’s solution, 1153t
Lumiracoxib, 964–965, 970t
chemistry, 987
COX isoform selectivity, 962f
dosage and administration
of, 987
pharmacology of, 962f
plasma pharmacokinetics of, 962f
therapeutic uses of, 987
Lung(s)
ABC transporters in, 106t
alpha adrenergic receptors in, 203t
in autonomic nervous system,
178t
drug delivery to, 1034–1035
eicosanoids and, 947
in pulmonary absorption, 22–23
Lung cancer
drugs for, 1668t–1670t
small-cell, drugs for, 1668t–1670t
Lung flukes, 1449
Lupreolide, 1119t
LUPRON (leuprolide), 1119t, 1668t–
1670t, 1764t, 1765, 1840
Lupus erythematosus
azathioprine for, 1820–1821
cutaneous, antimalarials for, 1819
cutaneous manifestations,
thalidomide for, 1824
discoid, retinoids for, 1811
drug-induced, 787
methotrexate for, 1820
subacute, retinoids for, 1811
Luteinizing hormone (LH), 1106t,
1117–1120
LUTREPULSE (gonadorelin acetate),
1119t
LYBREL (ethinyl estradiol/
levonorgesterol), 1836t
LYBREL (ethinyl estradiol/
levonorgestrel), 1835t
Lyme disease, penicillin for, 1487
Lymphatic filariasis, 1446, 1456
Lymphocyte function-associated
antigen-1 inhibition, 1019
Lymphogranuloma venereum (LGV),
1842t
2043
INDEX